Highlights Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Real-time Estimate Cboe BZX Other stock markets 03:33:42 2024-06-12 pm EDT			5-day change	1st Jan Change
6.095 ^USD	-0.08%		+33.33%	+120.64%

Jun. 01	Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting	CI
May. 16	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting	Jun. 01	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients	Apr. 08	MT
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
Black Diamond Therapeutics, Inc. Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM	Dec. 13	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Black Diamond Therapeutics, Inc. Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535	23-10-14	CI
Black Diamond Therapeutics, Inc. Doses First Patients in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer	23-09-11	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Black Diamond Therapeutics Discloses Institutional Shareholder Equity Stake Expansion; Shares Jump Premarket	23-07-10	MT
Black Diamond Therapeutics, Inc. Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families	23-06-27	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
BLACK DIAMOND THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-03-09	AQ
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI
Black Diamond Therapeutics Forms Antibody-Focused Precision Oncology Company Launchpad	22-12-12	MT
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company	22-12-12	AQ
Earnings Flash (BDTX) BLACK DIAMOND THERAPEUTICS Reports Q3 Loss $-0.60	22-11-08	MT
BLACK DIAMOND THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Black Diamond Therapeutics, Inc.

Equities

BDTX

US09203E1055

Highlights

Filters